WO2002085945A3 - Vhh single heavy chain antibody and a method for its preparation in a mammal - Google Patents

Vhh single heavy chain antibody and a method for its preparation in a mammal Download PDF

Info

Publication number
WO2002085945A3
WO2002085945A3 PCT/IB2002/002424 IB0202424W WO02085945A3 WO 2002085945 A3 WO2002085945 A3 WO 2002085945A3 IB 0202424 W IB0202424 W IB 0202424W WO 02085945 A3 WO02085945 A3 WO 02085945A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
preparation
heavy chain
chain antibody
single heavy
Prior art date
Application number
PCT/IB2002/002424
Other languages
French (fr)
Other versions
WO2002085945A2 (en
Inventor
Frank Grosveld
Original Assignee
Univ Erasmus
Frank Grosveld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus, Frank Grosveld filed Critical Univ Erasmus
Priority to JP2002583471A priority Critical patent/JP2005503129A/en
Priority to EP02738502A priority patent/EP1381630A2/en
Priority to MXPA03009785A priority patent/MXPA03009785A/en
Priority to BR0209204-2A priority patent/BR0209204A/en
Priority to CA002445255A priority patent/CA2445255A1/en
Publication of WO2002085945A2 publication Critical patent/WO2002085945A2/en
Publication of WO2002085945A3 publication Critical patent/WO2002085945A3/en
Priority to US10/692,918 priority patent/US20040142432A1/en
Priority to US12/833,132 priority patent/US8502014B2/en
Priority to US13/951,906 priority patent/US20140037616A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention relates to a method for the generation of single chain immunoglobulins in a mammal. In particular, the present invention relates to a method for the generation of single chain camelid VHH antibodies in a mammal which undergo the process of class-switching and affinity maturation found within antibody producing B cells. Single chain antibodies generated using the method of the present invention and the uses thereof are also described.
PCT/IB2002/002424 2001-04-24 2002-04-24 Vhh single heavy chain antibody and a method for its preparation in a mammal WO2002085945A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2002583471A JP2005503129A (en) 2001-04-24 2002-04-24 Immunoglobulin 1
EP02738502A EP1381630A2 (en) 2001-04-24 2002-04-24 Vhh single heavy chain antibody and a method for its preparation in a mammal
MXPA03009785A MXPA03009785A (en) 2001-04-24 2002-04-24 Vhh single heavy chain antibody and a method for its preparation in a mamal.
BR0209204-2A BR0209204A (en) 2001-04-24 2002-04-24 Immunoglobulin 1
CA002445255A CA2445255A1 (en) 2001-04-24 2002-04-24 Vhh single heavy chain antibody and a method for its preparation in a mammal
US10/692,918 US20040142432A1 (en) 2001-04-24 2003-10-24 Immunoglobulin 1
US12/833,132 US8502014B2 (en) 2001-04-24 2010-07-09 Method for the production of a single heavy chain antibody
US13/951,906 US20140037616A1 (en) 2001-04-24 2013-07-26 Immunoglobulin 1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110029.6A GB0110029D0 (en) 2001-04-24 2001-04-24 Transgenic animal
GB0110029.6 2001-04-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/692,918 Continuation US20040142432A1 (en) 2001-04-24 2003-10-24 Immunoglobulin 1

Publications (2)

Publication Number Publication Date
WO2002085945A2 WO2002085945A2 (en) 2002-10-31
WO2002085945A3 true WO2002085945A3 (en) 2003-03-06

Family

ID=9913359

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2002/002424 WO2002085945A2 (en) 2001-04-24 2002-04-24 Vhh single heavy chain antibody and a method for its preparation in a mammal
PCT/IB2002/002303 WO2002085944A2 (en) 2001-04-24 2002-04-24 Single chain camelid vhh antibodies, method for their production in a mammal and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002303 WO2002085944A2 (en) 2001-04-24 2002-04-24 Single chain camelid vhh antibodies, method for their production in a mammal and their uses

Country Status (16)

Country Link
US (6) US20040142432A1 (en)
EP (2) EP1381630A2 (en)
JP (3) JP2005503129A (en)
CN (2) CN1520424B (en)
AT (1) ATE358730T1 (en)
AU (1) AU2002256866B2 (en)
BR (2) BR0209207A (en)
CA (2) CA2445253C (en)
CY (1) CY1107669T1 (en)
DE (1) DE60219321T2 (en)
DK (1) DK1414858T3 (en)
ES (1) ES2284863T3 (en)
GB (1) GB0110029D0 (en)
MX (2) MXPA03009785A (en)
PT (1) PT1414858E (en)
WO (2) WO2002085945A2 (en)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CA2514834A1 (en) * 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
DK1737971T3 (en) 2004-01-20 2017-11-13 Merus Nv MIXTURES OF BINDING PROTEINS
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
BRPI0513577A (en) * 2004-07-22 2008-05-06 Univ Erasmus Medical Ct ligand molecules
US7615218B2 (en) * 2004-09-24 2009-11-10 Washington University Methods for determining and lowering caffeine concentration in fluids
FR2879605B1 (en) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
BRPI0706750A2 (en) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct heavy chain antibody generation in transgenic animals
JP5105468B2 (en) * 2006-12-05 2012-12-26 独立行政法人産業技術総合研究所 Creation of antibodies that function in cells and identification of proteins that control cell phenotypes
CA2672965C (en) 2006-12-19 2018-02-06 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
PL2336329T3 (en) 2007-06-01 2013-04-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
CA2720013C (en) 2008-04-03 2016-02-16 Bart De Strooper Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP3424526A1 (en) 2008-06-05 2019-01-09 Ablynx NV Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies
CN102164958A (en) * 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Humanization of rabbit antibodies using a universal antibody framework
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US9260508B2 (en) 2008-12-19 2016-02-16 Ablynx N.V. Method for generation of immunoglobulin sequences
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK2491056T3 (en) 2009-10-22 2021-10-25 Univ Twente VHH FOR USE IN TISSUE REPAIR, ORGAN REGENERATION, ORGAN REPLACEMENT AND TISSUE CONSTRUCTION
KR101553244B1 (en) 2009-12-10 2015-09-15 리제너론 파마슈티칼스 인코포레이티드 Mice that make heavy chain antibodies
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (en) 2010-02-08 2021-02-22 Regeneron Pharma Mouse common light chain
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
MX2018014787A (en) 2010-08-02 2023-02-14 Regeneron Pharma Mice that make binding proteins comprising vl domains.
EP2609119B1 (en) 2010-08-26 2017-10-18 Agrosavfe N.V. Chitinous polysaccharide antigen binding proteins
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
JP6181040B2 (en) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． Bispecific anti-CXCR7 immunoglobulin single variable domain
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
EP4282882A3 (en) 2011-06-21 2024-03-06 Vib Vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
ES2872081T3 (en) 2011-08-05 2021-11-02 Regeneron Pharma Humanized Universal Light Chain Mice
EP2753644A1 (en) * 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
JP2014531452A (en) 2011-09-19 2014-11-27 カイマブ・リミテッド Animals, repertoire and methods
WO2013059230A1 (en) 2011-10-17 2013-04-25 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
CN102372779A (en) * 2011-10-25 2012-03-14 李江伟 Camel single domain antibody with allinase activity as well as preparation method and application thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
CN102660551B (en) * 2012-02-09 2014-04-16 陈志南 VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application thereof
CA2865644A1 (en) * 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
JP2015512635A (en) 2012-03-28 2015-04-30 カイマブ・リミテッド Transgenic non-human vertebrates for expression of class-switched fully human antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
LT2838918T (en) 2012-04-20 2019-09-10 Merus N.V. Methods and means for the production of heterodimeric ig-like molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2855526B1 (en) 2012-05-24 2018-11-07 VIB vzw Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages
KR20240042174A (en) 2012-06-12 2024-04-01 리제너론 파마슈티칼스 인코포레이티드 Humanized non-human animals with restricted immunoglobulin heavy chain loci
PT3653049T (en) 2012-12-14 2023-11-14 Omniab Inc Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
CA2899693C (en) 2013-01-30 2023-03-14 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
ES2745772T3 (en) 2013-02-05 2020-03-03 Vib Vzw Acetylcholine Muscarinic Receptor Binding Agents and Uses thereof
SG11201505383UA (en) 2013-02-20 2015-08-28 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9617339B2 (en) 2013-03-15 2017-04-11 Vib Vzw Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
TR201819577T4 (en) * 2013-04-29 2019-01-21 Agrosavfe N V Agrochemical compositions containing antibodies that bind sphingolipids.
EP3013362B1 (en) 2013-06-28 2021-08-04 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103454413B (en) * 2013-09-04 2015-03-11 吉日木图 Bactrian camel specific antibody preparation method and immune detection method
CA2936728C (en) 2014-01-30 2023-06-20 Vib Vzw Opioid receptor binding agents and uses thereof
EP3119811B1 (en) 2014-03-21 2019-10-30 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
JP6636498B2 (en) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Non-human animals that make single domain binding proteins
PL3129400T3 (en) * 2014-04-08 2020-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals having humanized fc-gamma receptors
JP2018508224A (en) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Non-human animals that select light chain variable regions that bind antigen
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PL3328886T3 (en) 2015-07-29 2021-02-08 Allergan, Inc. Heavy chain only antibodies to ang-2
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
US10308711B2 (en) 2015-08-14 2019-06-04 Allergan, Inc. Heavy chain only antibodies to PDGF
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CN109438573B (en) * 2015-12-25 2020-11-10 中国农业科学院兰州兽医研究所 Porcine epidemic diarrhea virus M protein specific heavy chain antibody
CN109071627B (en) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 CD8 binding agents
JP2019507762A (en) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー CD20 binding single domain antibody
CN105777894A (en) * 2016-03-12 2016-07-20 长春力太生物技术有限公司 Method for preparing humanized camelidae single-domain antibody through transgenic rodent
CA3017813C (en) 2016-03-17 2021-12-07 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
CN109563141A (en) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 To the therapeutic targeting of cellular structures
US10544221B2 (en) 2016-05-20 2020-01-28 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
MX2019002256A (en) * 2016-08-24 2019-10-09 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies.
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018103093A1 (en) * 2016-12-09 2018-06-14 深圳华大基因研究院 Primer combination constructed by variable region immune repertoire of camelid antibody and use thereof
EP3332637A1 (en) * 2016-12-09 2018-06-13 Universitätsklinikum Hamburg-Eppendorf Vhh-containing heavy chain antibody and production thereof
KR20190104400A (en) 2017-01-19 2019-09-09 오픈 모노클로날 테크놀로지, 인코포레이티드 Human antibodies of transgenic rodent origin with multiple heavy chain immunoglobulin loci
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN113896792A (en) 2017-05-12 2022-01-07 哈普恩治疗公司 Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
MX2020003915A (en) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Trispecific proteins and methods of use.
MX2020003856A (en) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc B cell maturation antigen binding proteins.
US10017560B1 (en) 2017-11-16 2018-07-10 King Saud University Nanobody against begomoviruses
EP3732202A4 (en) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
JP2021513361A (en) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド Fibroblast binding substances and their use
KR20200138720A (en) 2018-03-30 2020-12-10 난징 레전드 바이오테크 씨오., 엘티디. Single-domain antibodies to LAG-3 and uses thereof
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
KR20220008866A (en) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM binding proteins and methods of use
US20220259329A1 (en) 2019-06-07 2022-08-18 Amgen Inc. Bispecific binding constructs
CN112574308A (en) 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 Antibodies targeting BCMA, bispecific antibodies and uses thereof
EP4106806A1 (en) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
EP4155319A1 (en) 2020-06-30 2023-03-29 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb binding protein and application thereof
EP4179095A1 (en) * 2020-07-13 2023-05-17 Kisoji Biotechnology Inc. Transgenic animals expressing heavy chain antibodies
IL303205A (en) 2020-12-03 2023-07-01 Amgen Inc Immunoglobuline constructs with multiple binding domains
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
WO2022156908A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method for preparing a lyophilized composition
WO2022157373A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2
WO2022221120A1 (en) 2021-04-16 2022-10-20 Bio-Techne Corporation Camelid anti-severe acute respiratory syndrome coronavirus antibodies
WO2022247826A1 (en) 2021-05-28 2022-12-01 和铂医药(上海)有限责任公司 Specific binding protein targeting pd-l1 and cd73
CA3228682A1 (en) 2021-08-18 2023-02-23 Harbour Biomed (Shanghai) Co., Ltd Anti-b7-h4 antibody, and preparation method therefor and use thereof
WO2023057508A1 (en) 2021-10-05 2023-04-13 Vrije Universiteit Brussel Fluorescently labeled immunoglobulin single variable domai ns
TW202342522A (en) 2022-03-07 2023-11-01 日商武田藥品工業股份有限公司 Affinity chromatographic production of clinical human igg products
EP4349374A1 (en) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849992A (en) * 1993-12-20 1998-12-15 Genzyme Transgenics Corporation Transgenic production of antibodies in milk
WO1999042077A2 (en) * 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
JP3804432B2 (en) 2000-10-17 2006-08-02 住友電装株式会社 Inspection unit and connector inspection apparatus using the same
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2042594B1 (en) 2000-11-17 2011-03-23 Kyowa Hakko Kirin Co., Ltd. Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
JP3939160B2 (en) * 2001-05-25 2007-07-04 独立行政法人科学技術振興機構 Methods for expressing foreign genes in the kidney
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
NZ536341A (en) 2002-05-17 2008-05-30 Kirin Holdings Kk Transgenic ungulates capable of human antibody production
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
BRPI0706750A2 (en) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct heavy chain antibody generation in transgenic animals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849992A (en) * 1993-12-20 1998-12-15 Genzyme Transgenics Corporation Transgenic production of antibodies in milk
WO1999042077A2 (en) * 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUEGGEMANN MARIANNE ET AL: "Strategies for expressing human antibody repertoires in transgenic mice.", IMMUNOLOGY TODAY, vol. 17, no. 8, 1996, pages 391 - 397, XP004034600, ISSN: 0167-5699 *
DAVIES JULIAN ET AL: "'Camelising' human antibody fragments: NMR studies on VH domains.", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 339, no. 3, 1994, pages 285 - 290, XP002011334, ISSN: 0014-5793 *
DAVIES JULIAN ET AL: "Single antibody domains as small recognition units: Design and in vitro antigen selection of camelized, human VH domains with improved protein stability.", PROTEIN ENGINEERING, vol. 9, no. 6, 1996, pages 531 - 537, XP000971767, ISSN: 0269-2139 *
RIECHMANN LUTZ ET AL: "Single domain antibodies: Comparison of camel VH and camelised human VH domains.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 25 - 38, XP004187632, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
US20040137570A1 (en) 2004-07-15
WO2002085944A2 (en) 2002-10-31
BR0209207A (en) 2005-02-09
WO2002085944A3 (en) 2004-03-04
EP1414858B1 (en) 2007-04-04
CA2445253A1 (en) 2002-10-31
DE60219321T2 (en) 2008-03-20
CA2445255A1 (en) 2002-10-31
BR0209204A (en) 2004-07-06
EP1414858A2 (en) 2004-05-06
CN1518559A (en) 2004-08-04
MXPA03009776A (en) 2005-03-07
CN1520424B (en) 2012-09-05
CA2445253C (en) 2012-04-10
US8502014B2 (en) 2013-08-06
JP2010013479A (en) 2010-01-21
DE60219321D1 (en) 2007-05-16
JP2005503129A (en) 2005-02-03
US20110004949A1 (en) 2011-01-06
ES2284863T3 (en) 2007-11-16
ATE358730T1 (en) 2007-04-15
DK1414858T3 (en) 2007-07-09
US20040142432A1 (en) 2004-07-22
JP4418159B2 (en) 2010-02-17
EP1381630A2 (en) 2004-01-21
CY1107669T1 (en) 2013-04-18
US20110004948A1 (en) 2011-01-06
CN1520424A (en) 2004-08-11
AU2002256866B2 (en) 2007-06-21
JP2005503128A (en) 2005-02-03
US8507748B2 (en) 2013-08-13
MXPA03009785A (en) 2005-03-07
GB0110029D0 (en) 2001-06-13
PT1414858E (en) 2007-05-31
WO2002085945A2 (en) 2002-10-31
US20140037616A1 (en) 2014-02-06
US20140033335A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
WO2002085945A3 (en) Vhh single heavy chain antibody and a method for its preparation in a mammal
EP2186884A3 (en) HCV-anti-core monoclonal antibody
EP1362093A4 (en) Rapid production of monoclonal antibodies
WO2006004663A3 (en) Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
HK1132750A1 (en) Monoclonal antibodies, cross-reactive antibodies and method for producing the same
WO2002103363A3 (en) Selection by avidity capture
SI1461428T1 (en) Method for producing hybrid antibodies
AU2003259718A1 (en) Methods for humanizing rabbit monoclonal antibodies
AU2002359851A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2005080432A3 (en) Cdr-repaired antibodies
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
WO2002036738A3 (en) Affinity maturation by competitive selection
GB2387847B (en) Method for producing monoclonal antibodies
WO2003055899A3 (en) Oxidized fungal antigens and methods of making and using thereof
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
EP1621555A4 (en) Immunogen, composition for immunological use, and method of producing antibody using the same
WO2001047953A3 (en) Antibodies against plasma cells
EP1270596A4 (en) Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method
AU2002238858A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
AU2002336248A1 (en) Methods for producing antibodies in mammals
AU1443900A (en) Glycoprotein antigens, antibodies specific thereto and method for producing same
AU2003204560A1 (en) Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
SI1414858T1 (en) Single chain camelid vhh antibodies, method for their production in a mammal, and their uses
AU2002311145A1 (en) Anti_human ovarian cancer -anti_cd3 bispecific antibody

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002583471

Country of ref document: JP

Ref document number: 10692918

Country of ref document: US

Ref document number: 2445255

Country of ref document: CA

Ref document number: PA/A/2003/009785

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002311544

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002738502

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 028125991

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002738502

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002738502

Country of ref document: EP